For the Inventor, By the Inventor

Enter assignee name

Guangdong, China

Shenzhen Targetrx, Inc.

USPTO Granted Patents = 36

EPO Patents = 22

Forward Citations = 18

Loading Chart...

Loading Chart...

8 inventors (with patents filed for the assignee):

Yihan Wang (36 out of 37 patents)

Huanyin Li (14 out of 14 patents)

Jiuyang Zhao (9 out of 9 patents)

4. Yixin Ai (7 out of 7 patents)

5. Xingye Ren (6 out of 6 patents)

6. Zhiqiang Liu (4 out of 15 patents)

7. Qingfeng Xing (4 out of 4 patents)

8. Jian Jin (1 out of 1 patent)

9. Yixin Al (0 patent)

36 patents: Sort by Forward Citations

1. 12365685 - Substituted fused aromatic ring derivative, composition and use thereof (2025-07-22),

2. 12312329 - Aminopyrimidine compound used for inhibiting activity of protein kinase (2025-05-27),

3. 12264151 - Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereof (2025-04-01),

4. 12129266 - Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof (2024-10-29),

5. 12116348 - Substituted benzimidazole compound and composition comprising same (2024-10-15),

6. 12077528 - Preparation method for deuterated macrocyclic compound (2024-09-03),

7. 12076320 - Diarylpyrazole compound, composition comprising same, and use thereof (2024-09-03),

8. 11840535 - Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity (2023-12-12),

9. 11802113 - Substituted pyrazole compounds, compositions containing same, and use thereof (2023-10-31),

10. 11746110 - Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity (2023-09-05),

11. 11718611 - Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereof (2023-08-08),

12. 11517561 - Macrocycle and composition comprising thereof (2022-12-06),

13. 11512074 - Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereof (2022-11-29),

14. 11485729 - Substituted pyridazinone compound (2022-11-01),

15. 11459334 - Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors (2022-10-04),

Shenzhen TargetRx, Inc. is a leading pharmaceutical research and consulting company based in Shenzhen, China. With a client-focused approach, we provide innovative solutions and insights to pharmaceutical companies, helping them optimize their products and strategies. Our team of experts is dedicated to delivering high-quality market research, patient profiling, and data analytics services. Through our cutting-edge technology and deep industry knowledge, we empower our clients to make informed decisions that drive success in the global healthcare market.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

36 Patents

#35 in Guangdong

#801 in China

#18,193 in the World

Guangdong, China

Shenzhen Targetrx, Inc.

Forward Citations = 18

8 inventors:

Yihan Wang (36 out of 37 patents)

Huanyin Li (14 out of 14 patents)

Jiuyang Zhao (9 out of 9 patents)

4. Yixin Ai (7 out of 7 patents)

5. Xingye Ren (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…